A Blinded, Randomized, Placebo-Controlled Trial of Percutaneous Laser Myocardial Revascularization to Improve Angina Symptoms in Patients With Severe Coronary Disease
Martin B. Leon, MD*,
Ran Kornowski, MD,
William E. Downey, MD,
Giora Weisz, MD,
Donald S. Baim, MD,
Robert O. Bonow, MD,
Robert C. Hendel, MD,
David J. Cohen, MD, MSc,
Ernest Gervino, DSc,
Roger Laham, MD,
Nicholas J. Lembo, MD,
Jeffrey W. Moses, MD and
Richard E. Kuntz, MD, MSc
Cardiovascular Research Foundation, Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, New York.
View larger version (18K):
[in a new window]
|
Figure 1 Freedom from major adverse cardiac events (MACE) from the index procedure to 12 months. Comparisons between groups at 12 months were not statistically significant.
|
|
View larger version (24K):
[in a new window]
|
Figure 2 Exercise duration(s) at baseline, at 6 months, and at 12 months of follow-up and the change in exercise duration between baseline and 6 months. The change in exercise duration was maintained at 12 months. All comparisons between groups were not statistically significant.
|
|
View larger version (18K):
[in a new window]
|
Figure 3 Canadian Cardiovascular Society angina class III or IV at baseline and 6- and 12-month follow-up. All comparisons between groups were not statistically significant.
|
|
|
